A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

Phase 2 Completed 28 enrolled Takara Bio Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.

Timeline

Start: 2017-05-25
Primary completion: 2018-06-30
Completion: 2018-12-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CANERPATUREV	Other / unclassified	1e+07 unknown	Other
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	Intravenous

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

Summary

Timeline

Drugs

Indications